Solid Biosciences Inc.
Solid Biosciences Inc. (SLDB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · SLDB · as of Jun 8, 2026
Key Statistics
Explore Solid Biosciences Inc. Data
sldb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 21 · Buy rate: 76.2%
The SLDB analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month price target is $17.00, representing +165.12% upside from the current price of $6.41.
Competitors & Peers
sldb competitorsSLDB
ANNX
AURA
AUTL
BNTC
DSGNStock Performance
Full HistoryAbout Solid Biosciences Inc.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene tran…
what is solid biosciences inc. · sldb stock overview · solid biosciences inc. company profile · who is solid biosciences inc. ceo · sldb NASDAQ · solid biosciences inc. headquarters · solid biosciences inc. business segments
About Stock Overview & Key Data
Solid Biosciences Inc. (SLDB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 26, 2018. As of the latest trading session, SLDB stock price is $6.41, with a market capitalization of $499.6M. The stock has returned +38.74% over the past 12 months and +13.65% year-to-date.
According to 21 Wall Street analysts, the consensus rating for Solid Biosciences Inc. stock is Buy, with an average 12-month price target of $17.00. In fiscal year 2025, Solid Biosciences Inc. reported revenue of — and net income of -$174.3M. For detailed data — including Solid Biosciences Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Solid Biosciences Inc. (SLDB) stock price is $6.41. The stock is traded on NASDAQ under the ticker symbol SLDB. The 52-week range is $3.67 – $8.87.